AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3880556
Drug: Prednisone (10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (10-15 mg daily)
Trial: 24394343
Drug: TRPV1 antagonist
RxNorm normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRPV1 antagonist AZD1386
Trial: 20881647
Drug: Enzastaurin 500
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin 500 mg orally daily (after a loading dose) plus pemetrexed 500 mg/m², carboplatin AUC 6, and bevacizumab 15 mg/kg intravenously every 21 days for four cycles.
Trial: 20881647
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus pemetrexed 500 mg/m², carboplatin AUC 6, and bevacizumab 15 mg/kg intravenously every 21 days for four cycles.
Trial: 18590751
Drug: Oral mucosal
RxNorm normalized name: Finafta Multi Oral Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mucosal wetness
Trial: 2169078
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fragmin) at a dose of 75 U/kg/day for 5 days (I group, n = 27)
Trial: 2169078
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Fragmin) at a dose of 150 U/kg/day for 5 days (II group, n = 29)
Trial: 75391
Drug: Dextropropoxyphene/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene/paracetamol
Trial: 28017166
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural steroid injections
Trial: 24495046
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) for 5 days and rectal enema
Trial: 22784287
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (RS)
Trial: 19960971
Drug: Yangyin Jiedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangyin Jiedu Huoxue Recipe (YJHR) plus conventional Western medical treatment
Trial: 19960971
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medical treatment only (Control)
Trial: 17613964
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg per day
Trial: 12118271
Drug: Hypertonic/hyperoncotic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic/hyperoncotic solution
Trial: 3305681
Drug: 15 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/die methimazole (group A)
Trial: 3305681
Drug: 30 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/die methimazole (group B)
Trial: 27733248
Drug: Lower fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower fat diet vs. lower carbohydrate diet (insulin sensitive women)
Trial: 27733248
Drug: Walnut-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-rich diet vs. lower carbohydrate diet (insulin sensitive women)
Trial: 27733248
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Sex hormone binding globulin)
Trial: 20171784
Drug: 120 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day oral raloxifene hydrochloride
Trial: 20171784
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day oral raloxifene hydrochloride
Trial: 14694042
Drug: Gabapentin (GPT)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GPT) 2,400 mg/day
Trial: 11068976
Drug: Extended 14‐session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended 14‐session cognitive‐behavioral group treatment (RPSG)
Trial: 11068976
Drug: Brief 2‐session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief 2‐session individual treatment using motivational interviewing (IAI)
Trial: 11068976
Drug: 4‐month delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐month delayed treatment control (DTC)
Trial: 8631163
Drug: 3000 IU
RxNorm normalized name: Cholecalciferol 3000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 IU bolus of heparin
Trial: 8631163
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU bolus of heparin
Trial: 1531927
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day for 6 weeks
Trial: 11209118
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day for 12 weeks
Trial: 1531927
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day for 24 weeks
Trial: 25878124
Drug: Nanoparticles (NPs)
RxNorm normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nanoparticles (NPs) targeted to inflammatory vascular molecules (VCAM‐1, E‐selectin, ICAM‐1).
Trial: 21562990
Drug: Polypharmacy (using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (using more than four medications)
Trial: 21562990
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication review at baseline
Trial: 16849762
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg bid with dexamethasone 4 mg daily
Trial: 16849762
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg bid with placebo
Trial: 15327614
Drug: Metronidazole (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1000 mg oral before abortion followed by 500 mg twice daily)
Trial: 9317068
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and metronidazole 500 mg b.i.d. (LCM) for 7 days
Trial: 9317068
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and bismuth subsalicylate 524 mg b.i.d. (LCB) for 7 days
Trial: 8403910
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to pregnant women
Trial: 8403910
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to non-pregnant women
Trial: 8403910
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg); additional dose for 6 non-pregnant women
Trial: 18510549
Drug: L-arginine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (18 g daily for 6 months)
Trial: 18510549
Drug: Control (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (18 g dextrose daily for 6 months)
Trial: 8770627
Drug: Slightly suppressive
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slightly suppressive L-thyroxine doses (50-200 micrograms/day)
Trial: 6117459
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg clotiazepam
Trial: 31600034
Drug: Oral nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nonsteroidal antiinflammatory therapy
Trial: 22299715
Drug: Bismuthyl ecabet
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuthyl ecabet 400 mg single dose
Trial: 22299715
Drug: Bismuthyl ecabet
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuthyl ecabet 800 mg single dose
Trial: 22299715
Drug: Bismuthyl ecabet
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuthyl ecabet 1200 mg single dose
Trial: 22299715
Drug: Bismuthyl ecabet
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuthyl ecabet 200 mg single dose
Trial: 22299715
Drug: Bismuthyl ecabet
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuthyl ecabet 1600 mg single dose
Trial: 22299715
Drug: Bismuthyl ecabet
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuthyl ecabet 1200 mg twice daily (multiple dose)
Trial: 11994358
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg ciclesonide inhaled twice daily
Trial: 21157021
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg bid)
Trial: 22716774
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU: n = 32)
Trial: 17013635
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules containing lactose
Trial: 30084152
Drug: Moisturizing gel
RxNorm normalized name: MOISTURIZING GEL
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing gel containing a pseudo‐ceramide and a eucalyptus extract, applied twice a day for 4 weeks.
Trial: 29053121
Drug: Cavinton R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton R for drop infusions (10 intravenously during 10 days) followed by cavinton R comforte in dose 10 mg, 1 tablet 3 times a day during 90 days
Trial: 29053121
Drug: Cavinton R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavinton R for drop infusions and cavinton R comforte
Trial: 21958025
Drug: 2 μg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg·kg(‐1) fentanyl (group F, n = 40)
Trial: 21958025
Drug: 2 mg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg·kg(‐1) tramadol (group T, n = 40)
Trial: 9679573
Drug: Function-preserving operations
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Function-preserving operations (e.g., EMR)
Trial: 1703598
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg intravenous isradipine
Trial: 1703598
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intravenous nifedipine
Trial: 28680540
Drug: Somatic Experiencing
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatic Experiencing (SE) in addition to treatment-as-usual (TAU)
Trial: 22247720
Drug: EPA +
RxNorm normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPA + vitamin C (500 mg EPA and 200 mg vitamin C)
Trial: 22247720
Drug: EPA +
RxNorm normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPA + placebo (500 mg EPA and placebo vitamin C)
Trial: 22247720
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + vitamin C (placebo EPA and 200 mg vitamin C)
Trial: 19535716
Drug: Ropivacaine infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine infiltration (20 mL of ropivacaine 0.75%)
Trial: 19535716
Drug: Control (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (IV acetaminophen combined with nalbuphine)
Trial: 15009362
Drug: Periprostatic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic saline injection
Trial: 9517769
Drug: Intravenous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate (MTX) 0.3 mg/kg once weekly plus daily oral low dose prednisone
Trial: 9517769
Drug: Concomitant prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant prednisone dose of 7.5 mg/day
Trial: 9517769
Drug: Weekly low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly low dose MTX in combination with low dose corticosteroids
Trial: 23672928
Drug: Temsirolimus 25mg
RxNorm normalized name: TEMSIROLIMUS 25MG/ML INJ,SOLN
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus 25mg i.v. administered weekly in 4 week cycles
Trial: 12526313
Drug: GM-CSF and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF and alpha-INF joint treatment (experimental group)
Trial: 9395275
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg
Trial: 9395275
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate 1 mg
Trial: 9395275
Drug: Oestradiol implants
RxNorm normalized name: Oestradiol Implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol implants 50 mg
Trial: 9395275
Drug: Oestradiol +
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol + medroxyprogesterone acetate (MPA) 2 mg + 5 mg
Trial: 9395275
Drug: Oestradiol +
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol + norethisterone acetate (NE) 2 mg + 1 mg
Trial: 8195446
Drug: Electronic pressure‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic pressure‐controlled probing set at 25 g
Trial: 20826244
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to aspirin
Trial: 28030444
Drug: Neostigmine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.05 mg/kg)
Trial: 23877110
Drug: Ultrasound-guided periradicular
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided periradicular injections
Trial: 23877110
Drug: Computed tomography-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computed tomography-controlled periradicular injections
Trial: 19491335
Drug: MK-0657 7
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0657 7 mg
Trial: 19491335
Drug: Carbidopa/levodopa 25/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa 25/250 mg (LD)
Trial: 10758447
Drug: Granisetron 40
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron 40 microg kg-1 plus dexamethasone 8 mg
Trial: 9438777
Drug: Irbesartan (AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (AT1 angiotensin II receptor antagonist)
Trial: 3468891
Drug: Low-tar cigarettes
RxNorm normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-tar cigarettes (5 mg/cig.)
Trial: 3468891
Drug: Medium-tar cigarettes
RxNorm normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-tar cigarettes (15 mg/cig.)
Trial: 31237947
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg/d for 24 weeks
Trial: 29391360
Drug: Gabapentin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (up to 2700 mg)
Trial: 26897383
Drug: Fixed-dose glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed-dose glucagon stimulation test (FD-GST: 1 or 1.5 mg in patients >90 kg)
Trial: 26897383
Drug: Weight-based glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weight-based glucagon stimulation test (WB-GST: 0.03 mg/kg)
Trial: 26897383
Drug: Fixed-dose glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed-dose glucagon stimulation test (FD-GST)
Trial: 20003095
Drug: Alverine citrate
RxNorm normalized name: alverine citrate
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alverine citrate 60 mg with simeticone 300 mg three times daily for 4 weeks
Trial: 12744893
Drug: Men C-CRM(197)
RxNorm normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [CHANCHI Vitamin C Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men C-CRM(197) conjugate vaccine
Trial: 6362017
Drug: Quinine 10
RxNorm normalized name: quinine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 10 mg base per kg body wt. 8 hourly for 7 days
Trial: 6362017
Drug: Quinine 10
RxNorm normalized name: quinine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 10 mg base per kg body wt. 8 hourly for the first 4 days then 15 mg base per kg body wt. 8 hourly for the next 3 days
Trial: 6362017
Drug: Quinine 10
RxNorm normalized name: quinine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 10 mg base per kg body wt. 8 hourly for 7 days and then sulfadoxine 30 mg per kg body wt. and pyrimethamine 1.5 mg per kg body wt.
Trial: 28362563
Drug: Cadila MMR
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadila MMR vaccine
Trial: 28362563
Drug: Serum MMR
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum MMR vaccine
Trial: 22081489
Drug: Pomalidomide (0.5‐3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (0.5‐3.5 mg/day) with or without prednisone
Trial: 19176240
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy targeting blood glucose concentrations of 2.8-4.4 mmol/L in infants and 3.9-5.6 mmol/L in children throughout PICU stay (n=349)
Trial: 19176240
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy to prevent blood glucose from exceeding 11.9 mmol/L (n=351)
Trial: 8734235
Drug: Corticosteroids (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (methylprednisolone 1.5 mg.kg‐1 intravenously at the beginning of surgery and 1.5 mg.kg‐1 iv daily for three days after surgery)
Trial: 1827006
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg isradipine twice daily
Trial: 7053912
Drug: Propranolol combined
RxNorm normalized name: propranolol and other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol combined with lactate and glycerol infusions
Trial: 29946756
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (20,000 IU of cholecalciferol weekly for 24 weeks)
Trial: 24829053
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block (ISB) - 10 ml mepivacaine 1 % and 20 ml ropivacaine 0.375%
Trial: 16730604
Drug: Self-Administered (SA)
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Administered (SA)
Trial: 16730604
Drug: Interviewer-Administered (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-Administered (IA)
Trial: 16730604
Drug: Paper-and-Pencil Self-Administered
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-Pencil Self-Administered (SA)
Trial: 12738464
Drug: Infliximab 1
RxNorm normalized name: infliximab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab 1 mg/kg
Trial: 10874600
Drug: AAACa (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAACa (900 mg/day elemental calcium)
Trial: 10874600
Drug: AACa (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AACa (900 mg/day elemental calcium)
Trial: 10874600
Drug: CaCO3 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCO3 (900 mg/day elemental calcium)
Trial: 9059470
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (NO) at 40 ppm for 20 minutes
Trial: 9059470
Drug: Air (control)
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air (control) inhaled for 20 minutes